Mohrschladt MF - Search Results

1

TaqIB polymorphism in CETP gene: the influence on incidence of cardiovascular disease in statin-treated patients with familial hypercholesterolemia.

Mohrschladt MF, van der Sman-de Beer F, Hofman MK, van der Krabben M, Westendorp RG, Smelt AH. Mohrschladt MF, et al. Eur J Hum Genet. 2005 Jul;13(7):877-82. doi: 10.1038/sj.ejhg.5201426. Eur J Hum Genet. 2005. PMID: 15856070

2

C-reactive protein in patients with familial hypercholesterolemia: no effect of simvastatin therapy.

Mohrschladt MF, de Maat MP, Westendorp RG, Smelt AH. Mohrschladt MF, et al. Atherosclerosis. 2001 Aug;157(2):491-4. doi: 10.1016/s0021-9150(00)00754-1. Atherosclerosis. 2001. PMID: 11472751

3

Cardiovascular disease and mortality in statin-treated patients with familial hypercholesterolemia.

Mohrschladt MF, Westendorp RG, Gevers Leuven JA, Smelt AH. Mohrschladt MF, et al. Atherosclerosis. 2004 Feb;172(2):329-35. doi: 10.1016/j.atherosclerosis.2003.11.007. Atherosclerosis. 2004. PMID: 15019543

4

Modulating effect of the A-278C promoter polymorphism in the cholesterol 7alpha-hydroxylase gene on serum lipid levels in normolipidaemic and hypertriglyceridaemic individuals.

Hofman MK, Groenendijk M, Verkuijlen PJ, Jonkers IJ, Mohrschladt MF, Smelt AH, Princen HM. Hofman MK, et al. Among authors: mohrschladt mf. Eur J Hum Genet. 2004 Nov;12(11):935-41. doi: 10.1038/sj.ejhg.5201236. Eur J Hum Genet. 2004. PMID: 15241483

5

Hyperlipoproteinemia affects cytokine production in whole blood samples ex vivo. The influence of lipid-lowering therapy.

Mohrschladt MF, Weverling-Rijnsburger AW, de Man FH, Stoeken DJ, Sturk A, Smelt AH, Westendorp RG. Mohrschladt MF, et al. Atherosclerosis. 2000 Feb;148(2):413-9. doi: 10.1016/s0021-9150(99)00316-0. Atherosclerosis. 2000. PMID: 10657578 Clinical Trial.

6

Severe hypertriglyceridemia with insulin resistance is associated with systemic inflammation: reversal with bezafibrate therapy in a randomized controlled trial.

Jonkers IJ, Mohrschladt MF, Westendorp RG, van der Laarse A, Smelt AH. Jonkers IJ, et al. Among authors: mohrschladt mf. Am J Med. 2002 Mar;112(4):275-80. doi: 10.1016/s0002-9343(01)01123-8. Am J Med. 2002. PMID: 11893366 Clinical Trial.

7

Endotoxin-lipoprotein hypothesis.

Mohrschladt MF, Smelt AH, Westendorp RG. Mohrschladt MF, et al. Lancet. 2000 Dec 16;356(9247):2097. doi: 10.1016/s0140-6736(05)74305-1. Lancet. 2000. PMID: 11145515 No abstract available.

8

Statins and C-reactive protein.

Kluft C, de Maat MP, Gevers Leuven JA, Potter van Loon BJ, Mohrschladt MF. Kluft C, et al. Among authors: mohrschladt mf. Lancet. 1999 Apr 10;353(9160):1274. doi: 10.1016/s0140-6736(05)66951-6. Lancet. 1999. PMID: 10217112 No abstract available.

9

The neonatal heart has a relatively high content of total collagen and type I collagen, a condition that may explain the less compliant state.

Marijianowski MM, van der Loos CM, Mohrschladt MF, Becker AE. Marijianowski MM, et al. Among authors: mohrschladt mf. J Am Coll Cardiol. 1994 Apr;23(5):1204-8. doi: 10.1016/0735-1097(94)90612-2. J Am Coll Cardiol. 1994. PMID: 8144790 Free article.

10

A patient with a de novo t (6;9) and an interstitial duplication of (9)(q21.2q22.1).

Mohrschladt MF, Bijlsma EK, Sluijter S, De Coo RF, Hoovers JM, Leschot NJ. Mohrschladt MF, et al. Clin Dysmorphol. 1999 Jul;8(3):211-4. Clin Dysmorphol. 1999. PMID: 10457857

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

10 results

Search Page

Filters